A groundbreaking discovery from Northwestern Medicine may redefine the therapeutic landscape for aggressive cancers, revealing that a well-established asthma medication can be repurposed to combat tumor resistance and bolster immune responses. Published in the acclaimed journal Nature Cancer, this seminal study elucidates how tumors cleverly manipulate white blood cells to evade the immune system, and how blocking this mechanism can restore the body’s natural cancer-fighting abilities.
At the heart of this research lies the cysteinyl leukotriene receptor 1 (CysLTR1), a molecule historically associated with asthma pathophysiology and inflammatory responses. For decades, drugs such as montelukast have targeted CysLTR1 to mitigate asthma symptoms effectively. However, Northwestern scientists have unveiled a sinister role for this receptor in cancer biology, demonstrating that various tumors exploit CysLTR1 to suppress immune defense and promote their own growth. This revelation provides a compelling rationale for redirecting anti-asthma therapies toward oncology.
Through meticulous experimentation involving murine models and human tissues, the research team discovered that tumors can orchestrate an increase in neutrophils, a subtype of white blood cells normally tasked with combating infections. Instead of attacking cancer cells, these neutrophils are reprogrammed by tumors into immunosuppressive agents, creating a microenvironment that shields malignancies from immunotherapeutic interventions. The scientists pinpointed CysLTR1 as the molecular switch orchestrating this neutrophil-mediated immunosuppression.
Leveraging both genetic ablation techniques and pharmacological inhibition with montelukast, the researchers demonstrated a remarkable reduction in tumor growth across multiple cancer types, including notoriously treatment-resistant triple-negative breast cancer, melanoma, ovarian, colon, and prostate cancers. Crucially, these interventions not only decelerated tumor progression but also restored the efficacy of immune checkpoint therapies, even in cases where tumors had developed resistance.
The capacity to reprogram, rather than merely deplete, neutrophils represents a conceptual leap in cancer immunology. “By inhibiting CysLTR1, we encourage the transformation of neutrophils from tumor-promoting accomplices to tumor-attacking allies,” explains Dr. Bin Zhang, the study’s senior author and Johanna Dobe Professor of Cancer Immunology at Northwestern University Feinberg School of Medicine. This paradigm shift suggests that the innate immune system’s plasticity can be harnessed to overcome profound immunotherapy resistance commonly observed in aggressive cancers.
Augmenting their experimental data, the scientists conducted comprehensive analyses of human cancer samples and large-scale patient datasets. They identified a clear correlation between elevated CysLTR1 activity and poor clinical outcomes, including reduced survival rates and diminished responses to immunotherapy across diverse malignancies. This association underscores the clinical relevance of targeting CysLTR1 in the fight against cancer.
Given the pre-existing FDA approval of montelukast for asthma and allergies, these findings open the door to rapid translational applications. The drug’s safety profile and widespread availability significantly lower the barriers to clinical trials investigating its efficacy as an adjunct to current cancer therapies. The prospect of repurposing a familiar medication to improve outcomes for patients with intractable cancers is both promising and practical.
Future directions involve meticulous validation of this mechanism in human clinical trials, stratifying patients most likely to benefit from CysLTR1 inhibition, and optimizing combinatory regimens integrating montelukast with cutting-edge immunotherapeutic agents. The orchestration of these clinical investigations could herald a new era in cancer treatment, characterized by the strategic manipulation of the tumor microenvironment.
This study exemplifies the potential of re-examining well-characterized drugs through the lens of tumor immunology, unearthing novel therapeutic avenues from existing pharmacopoeia. It also highlights the importance of understanding the dualistic nature of immune cells within pathological contexts, where the same cell types can be co-opted to either harm or heal depending on molecular cues.
The insights from this work lay a concrete foundation for developing innovative treatments targeting myelopoiesis—the formation of myeloid cells like neutrophils—in cancer. By designing interventions that recalibrate immune cell function rather than indiscriminately eliminating cells, researchers move toward precision immunomodulation that could yield more durable and effective responses.
In sum, the findings represent a monumental stride in overcoming immune checkpoint therapy resistance, a formidable barrier in oncology. The ability to switch off the tumor’s immunosuppressive machinery and restore immune competence through a known, well-tolerated drug signals a beacon of hope for patients battling some of the deadliest cancers today.
Subject of Research: Role of cysteinyl leukotriene receptor 1 (CysLTR1) in tumor-induced immunosuppression and its blockade using montelukast to reprogram immune cells and overcome immune checkpoint therapy resistance.
Article Title: Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance.
News Publication Date: 19-May-2026
Web References: 10.1038/s43018-026-01174-7
Image Credits: Northwestern University / Senior study author Dr. Bin Zhang
Keywords: Cancer, Immunotherapy, Tumor Immunology, Neutrophils, Myelopoiesis, Montelukast, CysLTR1, Asthma Drug, Triple-negative Breast Cancer, Immune Checkpoint Therapy Resistance, Tumor Microenvironment, Immune Cell Reprogramming
